Brought to you by 
Abgenix, Chugai develop therapeutic antibodies
29 Sep 2021
Executive Summary
Under a multi-year deal, Abgenix (human antibody development) will use its XenoMouse technology to generate fully human monoclonal antibodies (MAbs) against two antigen targets it provides and two contributed by Japan's Chugai Pharmaceutical (just over 50% owned by Roche).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abgenix, Chugai develop therapeutic antibodies
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice